MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

amrecibart

  • Home
  • amrecibart
创新抗凝新方向：靶向凝血因子XI的 Amrecibart 与 Cenvacibart，助力更安全的血栓预防
Posted inHematology-Oncology news

Innovative Anticoagulation: Targeting Factor XI with Amrecibart and Cenvacibart for Safer Thrombosis Prevention

Posted by By MedXY 10/17/2026
Factor XI-targeted antibodies, amrecibart and cenvacibart, offer promising anticoagulation by selectively inhibiting intrinsic coagulation pathways, potentially reducing thrombosis without increasing bleeding risk.
Read More
  • Assessing Muscle Recovery: Responsiveness of the K-Force Grip Dynamometer in ICU-Acquired Weakness Patients
  • Long-Acting Injectable Cabotegravir-Rilpivirine Every 8 Weeks for Adolescents with HIV in Sub-Saharan Africa: Evidence from the LATA Trial and Contemporary Context
  • Optimizing Antibiotic Therapy for Community-Acquired Pneumonia in Children with Medical Complexity: Evidence for Narrow-Spectrum Use
  • Phenotype-Specific Mosaic Chromosomal Alterations in Systemic Sclerosis: Implications for Disease Subtypes and Clinical Outcomes
  • Impact of Donor Warm Ischemic Time on Biliary Complications After Laparoscopic Donor Right Hepatectomy: Insights From a Retrospective Cohort Study
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top